J. D. Adachi

Longitudinal assessment of health-related quality of life in osteoporosis: data from the population-based Canadian Multicentre Osteoporosis Study

D. Goltzman, C. Berger, T. Anastassiades, 2019, Osteoporosis International.

In vitro disintegration studies of weekly generic and branded risedronate sodium formulations available in Canada

J. D. Adachi, A. D. Walker, 2011, Current medical research and opinion.

Development and validation of the fracture risk scale home care (FRS-HC) that predicts one-year incident fracture: an electronic record-linked longitudinal cohort study

J. Hirdes, L. Giangregorio, G. Ioannidis, 2020, BMC Musculoskeletal Disorders.

Comparison of Speed of Sound Measures Assessed by Multisite Quantitative Ultrasound to Bone Mineral Density Measures Assessed by Dual-Energy X-Ray Absorptiometry in a Large Canadian Cohort: the Canadian Multicentre Osteoporosis Study (CaMos).

Jacques P. Brown, D. Hanley, K. Davison, 2016, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

Canadian normative data for the SF-36 health survey. Canadian Multicentre Osteoporosis Study Research Group.

Jacques P. Brown, J. Adachi, A. Tenenhouse, 2000, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

Oral contraceptive use and bone mineral density in premenopausal women: cross-sectional, population-based data from the Canadian Multicentre Osteoporosis Study.

S. A. Jackson, S. Kirkland, J. Adachi, 2001, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

A comparison of the effects of raloxifene and conjugated equine estrogen on bone and lipids in healthy postmenopausal women.

I. Reid, R. Eastell, N. Watts, 2004, Archives of internal medicine.

The Efficacy and Tolerability of Risedronate Once a week for the Treatment of Postmenopausal Osteoporosis

Jacques P. Brown, R. Lindsay, J. Adachi, 2002, Calcified Tissue International.

Fracture prediction and calibration of a Canadian FRAX® tool: a population-based report from CaMos

W. Leslie, C. Kovacs, G. Ioannidis, 2011, Osteoporosis International.

Cost-effectiveness of denosumab in the treatment of postmenopausal osteoporosis in Canada

R. Goeree, G. Ioannidis, D. Chau, 2012, Journal of medical economics.

Characteristics of hyperparathyroid states in the Canadian multicentre osteoporosis study (CaMos) and relationship to skeletal markers

C. Kovacs, D. Goltzman, C. Berger, 2015, Clinical endocrinology.